Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries
Pfizer
(NY:
PFE
)
29.66
-0.09 (-0.30%)
Official Closing Price
Updated: 7:00 PM EDT, Sep 19, 2024
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
All News about Pfizer
< Previous
1
2
...
28
29
30
31
32
33
34
35
36
...
99
100
Next >
European Medicines Agency Validates Type II Variation Application for PADCEV® (enfortumab vedotin) with KEYTRUDA® (pembrolizumab) for First-Line Treatment of Advanced Bladder Cancer
January 26, 2024
From
Pfizer Inc.
Via
Business Wire
How To Earn $500 A Month From Pfizer Stock Ahead Of Q4 Earnings Print
January 26, 2024
Pfizer Inc. (NYSE: PFE) is expected to release earnings results for its fourth quarter, before the opening bell on Jan. 30, 2024.
Via
Benzinga
ROSEN, TOP RANKED INVESTOR COUNSEL, Encourages BioNTech SE Investors to Secure Counsel Before Important Deadline in Securities Class Action - BNTX
January 25, 2024
WHY: NEW YORK, NY - (NewMediaWire) - January 25, 2024 - Rosen Law Firm, a global investor rights law firm, reminds purchasers of securities of BioNTech SE (NASDAQ: BNTX) between March 30, 2022 and...
Via
NewMediaWire
Topics
Lawsuit
Exposures
COVID-19
Financial
Legal
ROSEN, TOP RANKED INVESTOR COUNSEL, Encourages BioNTech SE Investors to Secure Counsel Before Important Deadline in Securities Class Action - BNTX
January 25, 2024
WHY: NEW YORK, NY - (NewMediaWire) - January 25, 2024 - Rosen Law Firm, a global investor rights law firm, reminds purchasers of securities of BioNTech SE (NASDAQ: BNTX) between March 30, 2022 and...
Via
TheNewswire.com
Topics
Lawsuit
Exposures
COVID-19
Financial
Legal
How Does Pfizer Fit Into a Well-Diversified Portfolio?
January 25, 2024
This tier 1 pharma stock is best-suited for one particular role in a broadly diversified portfolio.
Via
The Motley Fool
Pfizer Options Trading: A Deep Dive into Market Sentiment
January 24, 2024
Via
Benzinga
Beaten Down Blue Chips
January 25, 2024
While major US equity indices are now back to all-time highs, not everything has been working in the market lately, especially the list of stocks we're going to share with you today.
Via
Talk Markets
Top Dividend Stocks For 2024
January 25, 2024
What are some of top dividend stocks for 2024? After the eventful year that was 2023, it’s confusing to say the least.
Via
Talk Markets
3 Stocks to Sell Before Their Earnings Reports Disappoint in 2024
January 25, 2024
Here are three stocks to sell before earnings numbers are released during this challenging earnings season.
Via
InvestorPlace
What's Going On With Pfizer Stock Today?
January 25, 2024
Pfizer to announce Q4 2023 earnings on 30th Jan. Analysts project EPS loss of $(0.22) and $14.25B in revenues.
Via
Benzinga
5 top healthcare stocks for earnings growth in 2024
January 25, 2024
2024 holds promise for healthcare stocks, with Humana, Elevance, and others expected to boost earnings, as analysts say many industry pressures have been removed.
Via
MarketBeat
2 of the Best Stocks to Buy on a Dip in 2024
January 24, 2024
These stocks are down but don't count them out.
Via
The Motley Fool
Why Pfizer Is a Much Better Stock Than You Might Think
January 24, 2024
Don't write off this big pharma stock because of its current woes.
Via
The Motley Fool
How To Earn $500 Per Month From Pfizer Stock
January 23, 2024
Via
Benzinga
7 Over-Hyped Stocks to Sell Before They Plunge
January 25, 2024
It wasn't too long ago that these stocks were considered hot commodities. But now they're just overhyped stocks to sell.
Via
InvestorPlace
These 2 Growth Stocks Down 37% and 47% Are Screaming Buys for 2024
January 25, 2024
These beaten-down stocks should still be on your watch list.
Via
The Motley Fool
3 Growth Stocks Under $100 to Buy and Hold for Years
January 24, 2024
These stocks are trading at significantly reduced prices compared to where they were a few years ago.
Via
The Motley Fool
Could Pfizer Stock Help You Retire A Millionaire?
January 24, 2024
Pfizer shares have slipped in the double digits over the past year.
Via
The Motley Fool
ROSEN, A RANKED AND LEADING FIRM, Encourages BioNTech SE Investors to Secure Counsel Before Important Deadline in Securities Class Action - BNTX
January 23, 2024
Search for the latest press releases from publicly traded companies, private corporations, non-profits and other public sector organizations.
Via
NewMediaWire
Topics
Lawsuit
Exposures
COVID-19
Financial
Legal
Competitor Analysis: Evaluating Pfizer And Competitors In Pharmaceuticals Industry
January 22, 2024
Via
Benzinga
Wednesday Is Your Last Chance To Buy Pfizer Before The Dividend Payout
January 22, 2024
Via
Benzinga
ROSEN, A RANKED AND LEADING FIRM, Encourages BioNTech SE Investors to Secure Counsel Before Important Deadline in Securities Class Action - BNTX
January 23, 2024
WHY: NEW YORK, NY - (NewMediaWire) - January 23, 2024 - Rosen Law Firm, a global investor rights law firm, announces the filing of a class action lawsuit on behalf of purchasers of securities of...
Via
TheNewswire.com
Topics
Lawsuit
Exposures
COVID-19
Financial
Legal
Maximizing Tax Deductions: 3 Charity-Friendly Stocks to Consider
January 23, 2024
Pick charity-friendly stocks for a balanced approach to ethical investing. It's a perfect mix of financial wisdom and social responsibility.
Via
InvestorPlace
Bristol Myers, Exelixis Reveal 4-Year Follow-Up Results From Cancer Treatment Study
January 23, 2024
Bristol Myers Squibb & Exelixis Inc revealed four-year follow-up results from CheckMate -9ER trial.
Via
Benzinga
Bristol Myers Squibb's Combo Therapy Shows Sustained Benefits Over Pfizer's Cancer Drug In Kidney Cancer Patients After 8 Years Of Followup
January 23, 2024
Bristol Myer's Opdivo/Yervoy's long-term survival benefits in CheckMate-214 trial for advanced renal cell carcinoma. Significant reductions in risk of death, improved OS, PFS, and ORR after eight...
Via
Benzinga
Sarepta Therapeutics Inc.: Why it's a rising gene therapy star
January 23, 2024
Sarepta Therapeutics Inc. (NASDAQ: SRPT) is a leading commercial-stage biotech focused on developing precision gene therapy treatments for rare diseases.
Via
MarketBeat
ROSEN, GLOBAL INVESTOR COUNSEL, Encourages BioNTech SE Investors to Secure Counsel Before Important Deadline in Securities Class Action - BNTX
January 22, 2024
Search for the latest press releases from publicly traded companies, private corporations, non-profits and other public sector organizations.
Via
NewMediaWire
Topics
Lawsuit
Exposures
COVID-19
Financial
Legal
3 Ultra-High-Yield Dividend Stocks That Are Simply Too Cheap to Ignore
January 22, 2024
These stocks check off all the boxes for income and value investors.
Via
The Motley Fool
2 Incredible Growth Stocks That Are Screaming Buys for 2024
January 22, 2024
These healthcare businesses are compelling buys for very different reasons.
Via
The Motley Fool
ROSEN, TOP RANKED GLOBAL COUNSEL, Encourages BioNTech SE Investors with Losses to Secure Counsel Before Important Deadline in Securities Class Action - BNTX
January 21, 2024
Search for the latest press releases from publicly traded companies, private corporations, non-profits and other public sector organizations.
Via
NewMediaWire
Topics
Lawsuit
Exposures
COVID-19
Financial
Legal
< Previous
1
2
...
28
29
30
31
32
33
34
35
36
...
99
100
Next >
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.